articleJournal of Clinical InvestigationAug 6, 2008BRONZE OA

Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1

Hôpital Necker-Enfants Malades · Université Paris Cité · +11 more institutions

PubMed
Indexed incrossrefdoajpubmed

Abstract

Previously, several individuals with X-linked SCID (SCID-X1) were treated by gene therapy to restore the missing IL-2 receptor gamma (IL2RG) gene to CD34+ BM precursor cells using gammaretroviral vectors. While 9 of 10 patients were successfully treated, 4 of the 9 developed T cell leukemia 31-68 months after gene therapy. In 2 of these cases, blast cells contained activating vector insertions near the LIM domain-only 2 (LMO2) proto-oncogene. Here, we report data on the 2 most recent adverse events, which occurred in patients 7 and 10. In patient 10, blast cells contained an integrated vector near LMO2 and a second integrated vector near the proto-oncogene BMI1. In patient 7, blast cells contained an…

Citation impact

1,826
total citations
FWCI
74.59
Percentile
100%
References
55
Citations per year

Authors

29

Topics & keywords

Keywords
  • Genetic enhancement
  • Cancer research
  • Insertional mutagenesis
  • Severe combined immunodeficiency
  • Leukemia
  • Biology
  • Progenitor cell
  • CDKN2A
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding